CN107287200B - The siRNA and its recombinant vector of specificity inhibition Eya2 gene expression and application - Google Patents
The siRNA and its recombinant vector of specificity inhibition Eya2 gene expression and application Download PDFInfo
- Publication number
- CN107287200B CN107287200B CN201710547935.5A CN201710547935A CN107287200B CN 107287200 B CN107287200 B CN 107287200B CN 201710547935 A CN201710547935 A CN 201710547935A CN 107287200 B CN107287200 B CN 107287200B
- Authority
- CN
- China
- Prior art keywords
- eya2
- sirna
- cell
- taxol
- drug
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 108020004459 Small interfering RNA Proteins 0.000 title claims abstract description 55
- 230000014509 gene expression Effects 0.000 title claims abstract description 52
- 101150092334 Eya2 gene Proteins 0.000 title claims abstract description 24
- 239000013598 vector Substances 0.000 title claims abstract description 16
- 230000005764 inhibitory process Effects 0.000 title abstract description 14
- 229930012538 Paclitaxel Natural products 0.000 claims abstract description 78
- 229960001592 paclitaxel Drugs 0.000 claims abstract description 78
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 claims abstract description 78
- 230000000692 anti-sense effect Effects 0.000 claims abstract description 18
- 239000003814 drug Substances 0.000 claims abstract description 13
- 229940079593 drug Drugs 0.000 claims abstract description 12
- 238000002360 preparation method Methods 0.000 claims abstract description 8
- 230000004048 modification Effects 0.000 claims description 6
- 238000012986 modification Methods 0.000 claims description 6
- 108091028043 Nucleic acid sequence Proteins 0.000 claims description 4
- 230000002401 inhibitory effect Effects 0.000 claims description 4
- 239000002773 nucleotide Substances 0.000 claims 4
- 125000003729 nucleotide group Chemical group 0.000 claims 4
- 210000004027 cell Anatomy 0.000 abstract description 73
- 108090000623 proteins and genes Proteins 0.000 abstract description 22
- 206010061535 Ovarian neoplasm Diseases 0.000 abstract description 15
- 102000004169 proteins and genes Human genes 0.000 abstract description 13
- 210000004881 tumor cell Anatomy 0.000 abstract description 13
- 206010033128 Ovarian cancer Diseases 0.000 abstract description 12
- 206010059866 Drug resistance Diseases 0.000 abstract description 10
- 230000012292 cell migration Effects 0.000 abstract description 10
- 230000004663 cell proliferation Effects 0.000 abstract description 10
- 230000006907 apoptotic process Effects 0.000 abstract description 8
- 230000002441 reversible effect Effects 0.000 abstract description 8
- 239000003560 cancer drug Substances 0.000 abstract description 6
- 108020004999 messenger RNA Proteins 0.000 abstract description 5
- 238000011282 treatment Methods 0.000 abstract description 5
- 206010006187 Breast cancer Diseases 0.000 abstract description 3
- 208000026310 Breast neoplasm Diseases 0.000 abstract description 3
- 206010060862 Prostate cancer Diseases 0.000 abstract description 3
- 208000000236 Prostatic Neoplasms Diseases 0.000 abstract description 3
- 208000022033 carcinoma of urethra Diseases 0.000 abstract description 3
- 201000005243 lung squamous cell carcinoma Diseases 0.000 abstract description 3
- 208000019065 cervical carcinoma Diseases 0.000 abstract description 2
- 208000010507 Adenocarcinoma of Lung Diseases 0.000 abstract 1
- 238000001890 transfection Methods 0.000 description 34
- 230000000694 effects Effects 0.000 description 23
- 238000000034 method Methods 0.000 description 18
- 239000013642 negative control Substances 0.000 description 16
- 239000013612 plasmid Substances 0.000 description 13
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 12
- 108020004414 DNA Proteins 0.000 description 12
- 238000011160 research Methods 0.000 description 12
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 10
- 239000003153 chemical reaction reagent Substances 0.000 description 9
- 238000001514 detection method Methods 0.000 description 9
- 238000011534 incubation Methods 0.000 description 8
- 108091030071 RNAI Proteins 0.000 description 7
- 238000006243 chemical reaction Methods 0.000 description 7
- 230000030279 gene silencing Effects 0.000 description 7
- 230000009368 gene silencing by RNA Effects 0.000 description 7
- 206010028980 Neoplasm Diseases 0.000 description 6
- 230000029087 digestion Effects 0.000 description 6
- 239000007788 liquid Substances 0.000 description 6
- 239000000047 product Substances 0.000 description 6
- 238000012360 testing method Methods 0.000 description 6
- 238000001262 western blot Methods 0.000 description 6
- 201000011510 cancer Diseases 0.000 description 5
- 238000012226 gene silencing method Methods 0.000 description 5
- 230000007246 mechanism Effects 0.000 description 5
- 239000000523 sample Substances 0.000 description 5
- 241000894006 Bacteria Species 0.000 description 4
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 4
- 241000283707 Capra Species 0.000 description 4
- 102000003952 Caspase 3 Human genes 0.000 description 4
- 108090000397 Caspase 3 Proteins 0.000 description 4
- 101000702488 Rattus norvegicus High affinity cationic amino acid transporter 1 Proteins 0.000 description 4
- 108091027967 Small hairpin RNA Proteins 0.000 description 4
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 4
- 229910052794 bromium Inorganic materials 0.000 description 4
- 230000004709 cell invasion Effects 0.000 description 4
- 238000002512 chemotherapy Methods 0.000 description 4
- 238000013461 design Methods 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 239000001963 growth medium Substances 0.000 description 4
- 238000007689 inspection Methods 0.000 description 4
- 239000012528 membrane Substances 0.000 description 4
- 239000000203 mixture Substances 0.000 description 4
- 108091008146 restriction endonucleases Proteins 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- WOVKYSAHUYNSMH-RRKCRQDMSA-N 5-bromodeoxyuridine Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(Br)=C1 WOVKYSAHUYNSMH-RRKCRQDMSA-N 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- 108010001336 Horseradish Peroxidase Proteins 0.000 description 3
- 102000003960 Ligases Human genes 0.000 description 3
- 108090000364 Ligases Proteins 0.000 description 3
- 238000002835 absorbance Methods 0.000 description 3
- 238000003556 assay Methods 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 230000003247 decreasing effect Effects 0.000 description 3
- 238000004925 denaturation Methods 0.000 description 3
- 230000036425 denaturation Effects 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 230000018109 developmental process Effects 0.000 description 3
- 238000005516 engineering process Methods 0.000 description 3
- 239000012634 fragment Substances 0.000 description 3
- 108010082117 matrigel Proteins 0.000 description 3
- 230000005012 migration Effects 0.000 description 3
- 238000013508 migration Methods 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 238000000746 purification Methods 0.000 description 3
- 238000010839 reverse transcription Methods 0.000 description 3
- 238000012216 screening Methods 0.000 description 3
- 239000004055 small Interfering RNA Substances 0.000 description 3
- 241000894007 species Species 0.000 description 3
- 239000006228 supernatant Substances 0.000 description 3
- 230000004083 survival effect Effects 0.000 description 3
- 238000003786 synthesis reaction Methods 0.000 description 3
- 102000040650 (ribonucleotides)n+m Human genes 0.000 description 2
- 108020005544 Antisense RNA Proteins 0.000 description 2
- 102100031181 Glyceraldehyde-3-phosphate dehydrogenase Human genes 0.000 description 2
- 241000700605 Viruses Species 0.000 description 2
- 230000002159 abnormal effect Effects 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 230000003698 anagen phase Effects 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 230000007910 cell fusion Effects 0.000 description 2
- 239000006285 cell suspension Substances 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 239000003184 complementary RNA Substances 0.000 description 2
- 238000002247 constant time method Methods 0.000 description 2
- 230000007423 decrease Effects 0.000 description 2
- 239000008367 deionised water Substances 0.000 description 2
- 229910021641 deionized water Inorganic materials 0.000 description 2
- 238000010586 diagram Methods 0.000 description 2
- 235000019441 ethanol Nutrition 0.000 description 2
- 239000012530 fluid Substances 0.000 description 2
- 238000013467 fragmentation Methods 0.000 description 2
- 238000006062 fragmentation reaction Methods 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 238000003209 gene knockout Methods 0.000 description 2
- 210000004907 gland Anatomy 0.000 description 2
- 108020004445 glyceraldehyde-3-phosphate dehydrogenase Proteins 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 239000002502 liposome Substances 0.000 description 2
- 210000004072 lung Anatomy 0.000 description 2
- 230000010534 mechanism of action Effects 0.000 description 2
- 239000013600 plasmid vector Substances 0.000 description 2
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical class [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 description 2
- 229920002981 polyvinylidene fluoride Polymers 0.000 description 2
- 230000035755 proliferation Effects 0.000 description 2
- 238000004064 recycling Methods 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 238000003757 reverse transcription PCR Methods 0.000 description 2
- 108091092562 ribozyme Proteins 0.000 description 2
- 239000012679 serum free medium Substances 0.000 description 2
- 230000001629 suppression Effects 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 238000013518 transcription Methods 0.000 description 2
- 230000035897 transcription Effects 0.000 description 2
- 239000012096 transfection reagent Substances 0.000 description 2
- 230000000007 visual effect Effects 0.000 description 2
- WZUVPPKBWHMQCE-XJKSGUPXSA-N (+)-haematoxylin Chemical compound C12=CC(O)=C(O)C=C2C[C@]2(O)[C@H]1C1=CC=C(O)C(O)=C1OC2 WZUVPPKBWHMQCE-XJKSGUPXSA-N 0.000 description 1
- CZVCGJBESNRLEQ-UHFFFAOYSA-N 7h-purine;pyrimidine Chemical compound C1=CN=CN=C1.C1=NC=C2NC=NC2=N1 CZVCGJBESNRLEQ-UHFFFAOYSA-N 0.000 description 1
- 235000011330 Armoracia rusticana Nutrition 0.000 description 1
- 240000003291 Armoracia rusticana Species 0.000 description 1
- 208000005623 Carcinogenesis Diseases 0.000 description 1
- 108090000994 Catalytic RNA Proteins 0.000 description 1
- 102000053642 Catalytic RNA Human genes 0.000 description 1
- 206010010254 Concussion Diseases 0.000 description 1
- 229920000742 Cotton Polymers 0.000 description 1
- 241000255581 Drosophila <fruit fly, genus> Species 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102100030862 Eyes absent homolog 2 Human genes 0.000 description 1
- 208000009849 Female Genital Neoplasms Diseases 0.000 description 1
- 229940122498 Gene expression inhibitor Drugs 0.000 description 1
- 101710088172 HTH-type transcriptional regulator RipA Proteins 0.000 description 1
- WZUVPPKBWHMQCE-UHFFFAOYSA-N Haematoxylin Natural products C12=CC(O)=C(O)C=C2CC2(O)C1C1=CC=C(O)C(O)=C1OC2 WZUVPPKBWHMQCE-UHFFFAOYSA-N 0.000 description 1
- 101000938438 Homo sapiens Eyes absent homolog 2 Proteins 0.000 description 1
- 102100034343 Integrase Human genes 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 108091034117 Oligonucleotide Proteins 0.000 description 1
- 108010019160 Pancreatin Proteins 0.000 description 1
- 235000016408 Podocarpus macrophyllus Nutrition 0.000 description 1
- 238000012181 QIAquick gel extraction kit Methods 0.000 description 1
- 238000012228 RNA interference-mediated gene silencing Methods 0.000 description 1
- 108010092799 RNA-directed DNA polymerase Proteins 0.000 description 1
- 241000244173 Rhabditis Species 0.000 description 1
- 108091081024 Start codon Proteins 0.000 description 1
- 239000006180 TBST buffer Substances 0.000 description 1
- 244000162450 Taxus cuspidata Species 0.000 description 1
- 235000009065 Taxus cuspidata Nutrition 0.000 description 1
- 102000004142 Trypsin Human genes 0.000 description 1
- 108090000631 Trypsin Proteins 0.000 description 1
- 101150063416 add gene Proteins 0.000 description 1
- AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 1
- 229960000723 ampicillin Drugs 0.000 description 1
- 238000000540 analysis of variance Methods 0.000 description 1
- 238000000137 annealing Methods 0.000 description 1
- 108010078837 aspartyl-glutamyl-valyl-aspartyl-p-nitroanilide Proteins 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 230000036952 cancer formation Effects 0.000 description 1
- 231100000504 carcinogenesis Toxicity 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 230000022131 cell cycle Effects 0.000 description 1
- 230000003915 cell function Effects 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 230000009514 concussion Effects 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 239000013068 control sample Substances 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 230000003013 cytotoxicity Effects 0.000 description 1
- 231100000135 cytotoxicity Toxicity 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 238000012938 design process Methods 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 230000003828 downregulation Effects 0.000 description 1
- 238000004043 dyeing Methods 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 230000013020 embryo development Effects 0.000 description 1
- 229940088598 enzyme Drugs 0.000 description 1
- 101150110316 eya gene Proteins 0.000 description 1
- 230000004373 eye development Effects 0.000 description 1
- 230000037440 gene silencing effect Effects 0.000 description 1
- 208000014829 head and neck neoplasm Diseases 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 230000003308 immunostimulating effect Effects 0.000 description 1
- 230000008676 import Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000002779 inactivation Effects 0.000 description 1
- 238000010832 independent-sample T-test Methods 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 230000009545 invasion Effects 0.000 description 1
- 238000011068 loading method Methods 0.000 description 1
- HWYHZTIRURJOHG-UHFFFAOYSA-N luminol Chemical compound O=C1NNC(=O)C2=C1C(N)=CC=C2 HWYHZTIRURJOHG-UHFFFAOYSA-N 0.000 description 1
- 239000006166 lysate Substances 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 208000026037 malignant tumor of neck Diseases 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 1
- 238000010232 migration assay Methods 0.000 description 1
- 238000010369 molecular cloning Methods 0.000 description 1
- 230000036457 multidrug resistance Effects 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 238000001543 one-way ANOVA Methods 0.000 description 1
- 238000005457 optimization Methods 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 229940055695 pancreatin Drugs 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 230000035479 physiological effects, processes and functions Effects 0.000 description 1
- 238000007747 plating Methods 0.000 description 1
- 229910052697 platinum Inorganic materials 0.000 description 1
- 238000002264 polyacrylamide gel electrophoresis Methods 0.000 description 1
- 230000001124 posttranscriptional effect Effects 0.000 description 1
- 230000032361 posttranscriptional gene silencing Effects 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 239000003531 protein hydrolysate Substances 0.000 description 1
- 238000010814 radioimmunoprecipitation assay Methods 0.000 description 1
- 238000003259 recombinant expression Methods 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 238000000611 regression analysis Methods 0.000 description 1
- 230000008521 reorganization Effects 0.000 description 1
- 238000012827 research and development Methods 0.000 description 1
- 210000001525 retina Anatomy 0.000 description 1
- 239000012313 reversal agent Substances 0.000 description 1
- 239000002356 single layer Substances 0.000 description 1
- 235000020183 skimmed milk Nutrition 0.000 description 1
- 238000010583 slow cooling Methods 0.000 description 1
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 1
- 238000007711 solidification Methods 0.000 description 1
- 230000008023 solidification Effects 0.000 description 1
- 238000002798 spectrophotometry method Methods 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 238000002626 targeted therapy Methods 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 239000012588 trypsin Substances 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/14—Type of nucleic acid interfering N.A.
- C12N2310/141—MicroRNAs, miRNAs
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/33—Chemical structure of the base
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- General Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Microbiology (AREA)
- Plant Pathology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Physics & Mathematics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
The invention discloses the siRNA of species specificity inhibition Eya2 gene expression and its recombinant vector to apply in reversing oophoroma taxol resistance with it, belongs to molecular biology and biomedicine technical field.The siRNA, including positive-sense strand and antisense strand, positive-sense strand: 5 '-UAGUUCUACCAUUUCCUUGUA-3 '；Antisense strand: 5 '-CAAGGAAAUGGUAGAACUAGU-3 '.SiRNA provided by the invention can specific, efficiently inhibit the mRNA and protein expression of Eya2 gene, reduce tumor cell proliferation, increase apoptosis of tumor cells, reduces tumor cell migration and invasive ability, and can effectively reverse ovarian cancer cell to the drug resistance of taxol.The present invention also provides the application of the Eya2siRNA and its recombinant vector in the drug of preparation treatment oophoroma, prostate cancer, breast cancer, adenocarcinoma of lung, squamous cell lung carcinoma, carcinoma of urethra, cervical carcinoma or reverse ovarian cancer drug-resistant.
Description
Technical field
The present invention relates to molecular biology and biomedicine technical field, a specially species specificity inhibits Eya2 gene table
The siRNA and its recombinant vector that reach and application.
Background technique
It is the sequence specific post transcriptional base being widely present in animals and plants that RNA, which interferes (RNA interference, RNAi),
Because of Silencing Mechanisms.Discovery for the first time will in beautiful new rhabditis axei C.Elegans body by American scientist Andrew Fire in 1998
The inhibition of at least 10 times GEM 132s of gene silencing effect caused by the mixture (i.e. dsRNA) of positive-sense strand and antisense strand
Effect, and same gene suppression can be induced in filial generation.The mechanism study of RNAi phenomenon is shown micro
SiRNA can make a large amount of target RNA silencings by posttranscriptional gene silencing, and it is this efficiently, special degradation cognate rna so as to cause
The key molecules of sequence specific gene silencing are the small double chain oligonucleotide of a length of 21-23 base, also referred to as siRNA
(siRNA).Further study show that shorter than 21bp or being longer than the double-stranded RNA of 25bp and being unable to effectively start RNAi, Er Qieqi
As soon as there is a base mispairing in as long as, obviously decline even disappears the effect of gene silencing, has fully demonstrated the spy of siRNA effect
It is anisotropic.
Show that the siRNA of powerful gene silencing efficiency attracts attention as the great discovery of biotechnology in recent years,
It is that gene functional research is strong exactly because it has the function of that specificity and high efficiency block the gene of homologous gene to inhibit
Tool.The advantage and characteristic that siRNA has many conventional methods incomparable.Although having some inhibition specific gene tables at present
The method reached, such as antisense RNA, gene knockout (knockout), but siRNA shows and is substantially better than the excellent of these technologies
Gesture: compared with antisense RNA, it has higher specificity and duration；Compared with the gene knockout of complicated and time consumption, siRNA is
More simple and effective means.It is widely used in the research of malignant tumour mechanism as the method for gene silencing currently with siRNA,
The key point of research, which is mainly concentrated in, improves gene silencing efficiency, including the selection of target gene site, the optimization of import system
With the influence etc. to host cell function, and the efficient targeted therapy strategy of the tomour specific based on the technology has thus been pushed
Research and development process.
Oophoroma is one of most common gynecologic malignant tumor, and case fatality rate occupies the first place of all kinds of gynecological tumors.Oophoroma
The generation that maximum obstacle is tumor cell drug resistance is treated, multidrug resistance especially occurs.As platinum class/taxol is medication combined
The implementation of chemotherapy, the first chemotherapy side effect rate of oophoroma is up to 80%.But Most patients recur in 2~3 years.After recurrence
Oophoroma, even if the chemotherapeutics entirely different using mechanism of action again, also generates drug resistance, to make survival rate after oncotherapy
It cannot significantly improve.The five year survival rate of advanced ovarian cancer is hovered always 20~30%.After high relapse rate and recurrence
High resistant rate is one of most important reason of oophoroma high mortality, and it is swollen at present for finding the drug resistant solution of chemotherapy in ovarian cancer
The important topic of tumor research.
Molecular targeted agents and chemotherapy combined application are the current raising most promising treatments of malignant tumor patient survival rate
Method.Eya2 (EYA transcriptional coactivator and phosphatase 2) be Eya family member it
One, it is a kind of important transcription regulatory factor.Eya is found as the gene that can control drosophila eye development earliest, dynamic in vertebra
In object and invertebrate, the nuclear factor of Eya gene coding can promote eye to develop, and be to constitute retina to determine gene net
The important member of network.Studies have shown that Eya2 later is prevalent in various organisms, and upper highly conserved evolving, it joins
With the important physiology course such as cell cycle regulating, tissue differentiation and allelotaxis in embryo development procedure, Eya2 gene hair
It is abnormal that raw mutation will lead to a variety of allelotaxis.In recent years, there are some researchs in oophoroma, prostate cancer, breast cancer, lung successively
Gland cancer, carcinoma of urethra, all detects that the expression of Eya2 is increased in tissue in cervical carcinoma at squamous cell lung carcinoma, although up to the present
Concrete function and its mechanism of action of the Eya2 in tumour generation and unclear, but Eya2 has taken part in the development process of tumour
Through gradually being recognized.
We are earlier research shows that Eya2 has abnormal raising in oophoroma taxol resistance cell strain A2780/Taxol
The phenomenon that, but whether the gene is related with ovarian tumors and ovarian cancer drug-resistant need further to study.Therefore, using RNAi
Technology interferes Eya2 gene expression in ovarian cancer drug-resistant cell strain, will be the important supplement to ovarian tumors mechanism,
It is the important exploration and application treated to oophoroma and its drug resistance.
Summary of the invention
The purpose of the present invention is to provide the siRNA that a species specificity inhibits Eya2 gene expression, are used for ovarian tumors
Mechanism Study.It is another object of the present invention to provide the siRNA in preparation treatment oophoroma and to reverse oophoroma taxol
Application in drug resistant drug.
To achieve the above object, the present invention adopts the following technical scheme:
3 pairs of present invention design, synthesis specificity inhibit the siRNA of Eya2 gene expression, and it is resistance to be transfected into oophoroma taxol
In medicine cell strain A2780/Taxol, as a result, it has been found that S1 inhibits the interference effect of Eya2 gene expression most obvious.
The present invention provides the siRNA (S1) that a species specificity inhibits Eya2 gene expression, including positive-sense strand and antisense strand,
The positive-sense strand: 5 '-UAGUUCUACCAUUUCCUUGUA-3 ' (SEQ ID NO.1)；
The antisense strand: 5 '-CAAGGAAAUGGUAGAACUAGU-3 ' (SEQ ID NO.2).
Preferably, 3 bases at 5 ' and 3 ' ends of the positive-sense strand and antisense strand carry out the modification of 2 '-methoxyl groups.This hair
Bright research has shown that siRNA (S1) stability after the modification of 2 '-methoxyl groups increases, and can improve its water for resisting ribozyme in vivo
The ability of solution reduces immunostimulation reaction, extends the action time of siRNA interference down regulation of gene expression, its effect is made to have height
Effect property, specificity.
The present invention provides a kind of rnai reagent boxes of DNA sequence dna comprising the coding siRNA.The kit
In comprising cloned the coding siRNA DNA sequence dna plasmid vector, in application, the plasmid vector is in eukaryocyte transfer
SiRNA needed for record expression, to achieve the purpose that silencing Eya2 gene expression.
The present invention provides a kind of recombinant vectors containing the DNA sequence dna for encoding the siRNA.Preferably, use
Initial carrier is slow virus carrier pLKO.1puro.
The present invention also provides the construction methods of recombinant vector, comprising:
(1) Eya2-S1 segment is synthesized, two restriction enzyme sites of Age I and EcoR I is selected to design it according to the sequence of S1
ShRNA sequence, sequence are as follows:
Positive-sense strand:
5’-CCGGACTAGTTCTACCATTTCCTTGTATTCAAGAGATACAAGGAAATGGTAGAACTAGTTTTTTT
GGTACC-3'(SEQ ID NO.7)；
Antisense strand:
5’-AATTGGTACCAAAAAAACTAGTTCTACCATTTCCTTGTATCTCTTGAATACAAGGAAATGGTAGA
ACTAGT-3'(SEQ ID NO.8)；
(2) annealing obtains the DNA fragmentation of Eya2-S1；
(3) pLKO.1-Eya2-sh1 recombinant vector is constructed with slow virus carrier pLKO.1puro.
SiRNA provided by the invention is capable of the expression of efficiently specific inhibition ovarian cancer cell Eya2 gene, reduces cell
Proliferation increases Apoptosis, reduces cell migration and invasive ability, therefore, the siRNA and recombinant vector are as Eya2 gene
Expression inhibiting agent can be applied in the research of tumor disease pathogenesis.
The present invention provides the siRNA and recombinant vector to prepare the application in Eya2 gene expression inhibitor.
The present invention provides the siRNA and recombinant vector to treat oophoroma, prostate cancer, breast cancer, lung gland in preparation
Application in cancer, squamous cell lung carcinoma, carcinoma of urethra or uterine neck cancer drug.
The present invention is studies have shown that after the taxol resistance strain A2780/Taxol transfection siRNA, and the cell strain is to Japanese yew
The sensibility of alcohol significantly improves, and reversing index is 6.67, illustrates siRNA provided by the invention to taxol resistance strain A2780/
The drug resistance of Taxol has the reversing effect of highly significant, therefore, treatment of the siRNA to oophoroma taxol resistance is reversed
With potential using value.
The present invention provides the siRNA and recombinant vector in the drug that preparation reverses oophoroma taxol resistance
Using.
It is that the present invention has the utility model has the advantages that
SiRNA provided by the invention can specific, efficiently inhibit the mRNA and protein expression of Eya2 gene, reduce swollen
Tumor cell proliferation increases apoptosis of tumor cells, reduces tumor cell migration and invasive ability, and can effectively reverse ovarian cancer cell
To the drug resistance of taxol, it is applied to Tumorigenesis research and preparation oncotherapy and reverses ovarian cancer drug-resistant treatment
Drug in, be of great significance.
Detailed description of the invention
Fig. 1 is that qRT-PCR detects A2780 cell and A2780/Taxol cell Eya2mRNA expression.
Fig. 2 is that Western Blotting detects A2780 cell and A2780/Taxol cell Eya2 protein expression.
Fig. 3 is that qRT-PCR detects S1, and A2780/Taxol cell Eya2mRNA is expressed after S2, S3 transfect 48h.
Fig. 4 is that Western Blotting detects S1, and S2, S3 transfect A2780/Taxol cell Eya2 albumen table after 72h
It reaches.
Fig. 5 is pLKO.1-Eya2-sh1 recombinant plasmid and insertion restriction enzyme site schematic diagram.
Fig. 6 is small hair fastener shRNA schematic diagram.U6 promoter instructs the transcription of the small hair fastener shRNA in downstream；Just including 23 S1
Adopted chain base, 23 S1 antisense strand bases.
Fig. 7 is A2780/Taxol cell Eya2 albumen after Western Blotting detection transfection pLKO.1-Eya2-sh1
Expression.
A2780/Taxol cell quantity and form become after Fig. 8 is phase contrast microscope observation transfection pLKO.1-Eya2-sh1
Change.
Fig. 9 is the proliferation of A2780/Taxol cell after bromine mark method detection transfection pLKO.1-Eya2-sh1.
Figure 10 is the apoptosis that Caspase3 Activity determination transfects A2780/Taxol cell after pLKO.1-Eya2-sh1.
Figure 11 is A2780/Taxol cell migration ability after cell scratch experiment detection transfection pLKO.1-Eya2-sh1.
Figure 12 be Transwell detection transfection pLKO.1-Eya2-sh1 after A2780/Taxol cell migration ability (A) and
Invasive ability (B).
Figure 13 is reverse of the A2780/Taxol cell to taxol resistance after transfection pLKO.1-Eya2-sh1.
Specific embodiment
Below with reference to embodiment, the invention will be further described.The purpose of method used in the examples below is more preferable
Ground understands the present invention, but is not limited to the present invention.Unless otherwise specified, experimental method involved in embodiment is conventional side
Method, experimental material used are the purchase of conventional reagent company.
Using 18.0 statistical analysis software of SPSS, each sample data is indicated with mean ± standard deviation (x ± s), between two groups
Difference examine (Independent-Sample T Test) with T, the inspection one-way analysis of variance (One- between multiple groups
Way ANOVA), IC50Using probit regression analysis, P < 0.05 has statistical difference.
Ovarian Cancer Cells A2780 and oophoroma taxol resistance cell strain A2780/Taxol are by Zhejiang Province's female reproduction
Health research key lab cell bank saves；
The anti-human GAPDH primary antibody (Cat.60004-1-Ig) of rabbit-anti people Eya2 primary antibody (Cat.11314-1-AP), mouse, horseradish mistake
Oxide enzyme marks goat anti-mouse IgG (H+L) secondary antibody (Cat.SA00001-1), horseradish peroxidase-labeled goat antirabbit
IgG (H+L) secondary antibody (Cat.SA00001-2) is purchased from Proteintech company；
Western Blotting Luminol Reagent detection kit (Cat.sc-2048) is purchased from Santa Cruz
Company；
CDNA Reverse Transcriptase kit PrimeScriptTMRT Master Mix (Cat.RR036A), quantitative fluorescent PCR inspection
Test agent box SYBR Premix Ex Taq (perfect Real time, Cat.DRR041A) is purchased from TaKaRa company；
Lipofectamine3000 transfection reagent box (Cat.L3000008) is purchased from Invitrogen company；
Carrier for expression of eukaryon selects RNAi carrier pLKO.1puro, shares non-profit organization derived from global scientist's plasmid
Addgene；
Restriction enzyme A ge I (Cat.R0552S), EcoR I (Cat.R0101S), Kpn I (Cat.R0142S) purchase
From NEB company；T4 ligase (Cat.2011A), DNA fragmentation purification kit (Cat.9761), DNA gel QIAquick Gel Extraction Kit
(Cat.9762), Plasmid DNA small scale purification kit (Cat.9760) is purchased from TaKaRa company；
SiRNA is synthesized by TaKaRa company；PCR primer and clone DNA are synthesized by Shanghai Sheng Gong bio-engineering corporation；
Pre-dyed albumen Marker (Cat.26616) is purchased from Fermentas company；
Bromine mark method cell proliferation detecting kit Cell Proliferation ELISA, BrdU (colorimetric,
Cat.11647229001) it is purchased from Roche company；
CaspACE Assay System (colorimetric, Cat.G7351) is purchased from Promega company；
Cell migration, invasive model Transwell Permeable Supports (Cat.3428) are public purchased from Corning
Department；
Lab-Tek II Chamber Slide System-Lab-Tek chamber slides system is purchased from Nunc company
(Cat.154526)；
BD MatrigelTMBasement Membrane Matirx matrix membrane (Cat.356234) is purchased from BD company；
SiRNA negative control AllStars Negative Control SiRNA (Cat.1027281) is public purchased from QIAGEN
Department；
It is ShiJi Co., Ltd that PAGE gel, which configures kit (Cat.CW0022M) purchased from health,；
0.45um pvdf membrane (Cat.IPVH00010) is purchased from Millipore company；
Taxol (Cat.P106868) is purchased from Aladdin company.
Eya2 expression is poor in embodiment 1. Ovarian Cancer Cells A2780 and its taxol resistance cell strain A2780/Taxol
Different research
One, real-time fluorescence quantitative RT-PCR (qRT-PCR) detects Eya2 gene mRNA expression
The culture medium abandoned in 6 orifice plates is inhaled after cultivating 48h, Trizol extracted total RNA, Thermo are used after being washed twice with PBS
Nano Drop2000 spectrophotometric determination RNA concentration, and press SYBR Premix Ex Taq (perfect Real time)
Kit specification operation.First step RNA denaturation, reaction system: RNA0.5ug goes RNA enzyme DEPC water to complement to 6.8ul；Instead
Answer condition: 70 DEG C of incubation 10min are placed on ice.Second step reverse transcription, reaction system: according to PrimeScript RT
Master Mix kit specification carries out reverse transcription；Reaction condition: after 42 DEG C of incubations 60min, 85 DEG C of inactivation 5min, -20 DEG C
It saves.
1ul reverse transcription product is taken to carry out quantitative fluorescent PCR reaction.PCR primer sequence:
5'-GGAGGAAATGGACTGGGCAA-3'；
5 '-CCAGCAAGTGACTCGGAACT-3 ', product length: 227bp；
Reaction condition: 95 DEG C of 10s, 95 DEG C of 5s, 6 DEG C of 30s, totally 40 recycle.
The expression quantity of Eya2mRNA in each group sample is calculated using 2- △ CT method.
As a result: as shown in Figure 1, A2780/Taxol cell is compared with its parental cell A2780, Eya2mRNA expression increases
High 65.11% (P < 0.05), shows that Eya2mRNA expression is significantly increased in taxol resistance cell strain.
Two, Western Blotting detects Eya2 protein expression
The culture medium abandoned in 6 orifice plates is inhaled after cultivating 72h, PBS is washed 3 times, it is added in RIPA protein lysate (hole 100ul/),
Piping and druming for several times, is incubated for 5min on ice, is allowed to sufficiently crack, 4 DEG C, and 12000 turns are centrifuged 5 minutes, collect supernatant, dispenses -20 DEG C of storages
It deposits；10ul loading, 8%SDS-PAGE electrophoresis, 200V, 10min are taken after 95 DEG C of denaturation 5min of each sample；100V, 100min；Turn
To pvdf membrane: 110V, 120min；60min is closed with the TBS confining liquid containing 5% skimmed milk power；Primary antibody is incubated for: Eya2 primary antibody (1:
2000), GAPDH primary antibody (1:5000) is incubated for 2h at room temperature；TBS washes film 10min × 3 time；Secondary antibody is incubated for: horseradish peroxidase
Mark goat anti-mouse IgG (H+L) secondary antibody (1:10000), horseradish peroxidase-labeled goat anti-rabbit igg (H+L) secondary antibody (1:
10000) it is incubated for 1h；TBST washes film 10min × 3 time, and TBS washes film 10min × 1 time；After ECL development, with Image Quant
LAS4000mini (GE Healthcare) is to scanning of image processing.
As a result: as shown in Fig. 2, A2780/Taxol cell is compared with its parental cell A2780, Eya2 protein expression
Significantly increase (P < 0.05).
Embodiment 2.Eya2siRNA design synthesis
Eya2 gene mRNA sequence (NM_005244.4) is discovered and seized in Genebank, with siDirect Ver2.0 software
(http://sidirect2.rnai.jp/) Photographing On-line obtains 3 couples of siRNA sequence (such as SEQ ID NO.1-SEQ ID
NO.6 shown in).In design process select and meanwhile meet three kinds of algorithms reported in the literature (Ui-Tei × Reynolds ×
Amarzguioui sequence), and the highest 23nt long fragment of siRNA action specificity is selected, which can avoid body in future
Interferon-like immune response occurs when interior experiment, selects 100nt after initiation codon, avoids 5 ' and 3 ' the end areas UTR, G/C content control
System is in 30-70%.Select the siRNA of 3 pairs of 23nt length as experiment screening interference fragment altogether, structure feature shows as positive-sense strand
Respectively plug-in there are two base with the end of antisense strand 3 ', design feature is as follows:
Then use BLASTN(https://blast.ncbi.nlm.nih.gov/Blast.cgi)It is online to carry out homology
Search excludes the sequence for having homology, avoids influence of the non-specific segment to siRNA specific effect effect as far as possible.
Finally 5 ' and 3 ' continuous 3 purine (pyrimidine) bases in end of positive-sense strand and antisense strand are carried out in chemical synthesis
2 '-OMe (2 '-methoxyl group) modification increases the chemical stability of siRNA molecule in the cell, extends siRNA and interferes gene expression
The time of downward and effect.Final sequence and modification such as table 1 and formula (I) is as follows:
Table 1
3. 3 couples of Eya2siRNA of embodiment interfere Eya2 gene in oophoroma taxol resistance strain A2780/Taxol
The detection and screening of effect
One, experimental group:
Normal group of 1.A2780/Taxol (not transfecting siRNA), hereinafter referred to as AR；
2.A2780/Taxol negative control group (transfection negative control siRNA), hereinafter referred to as AR-N；
3.A2780/Taxol experimental group (transfection S1), hereinafter referred to as AR-S1；
4.A2780/Taxol experimental group (transfection S2), hereinafter referred to as AR-S2；
5.A2780/Taxol experimental group (transfection S3), hereinafter referred to as AR-S3.
Two, grouping transfection
To ensure transfection efficiency, cytotoxicity is reduced, we are carried out using Lipofectamine3000 transfection reagent
SiRNA transfection.The day before transfection, trypsin digestion cell simultaneously count, and plating cells make it in transfection day density in six orifice plates
0.5×106/ ml, cell fusion to 70-90%.Every hole dilutes 5ul with 125 μ l serum-free OPTI-MEM culture mediums
3000 reagent of Lipofectamine simultaneously mixes well；SiRNA premixed liquid is prepared, with 125 μ l serum-free OPTI-MEM culture mediums
SiRNA to final concentration of 50nM is diluted, and is mixed well；It is added in diluted 3000 reagent of Lipofectamine
SiRNA premixed liquid (1:1) is incubated at room temperature 5min；Finally siRNA- liposome complex is added in cell, 37 DEG C, 5%
CO2In continue to cultivate.Eya2mRNA expression is detected after 48h, detects Eya2 protein expression after 72h.
Three, real-time fluorescence quantitative RT-PCR (qRT-PCR) detects Eya2 gene mRNA expression
Detecting step is the same, and the expression quantity of Eya2mRNA in each group sample is calculated using 2- △ CT method.
As a result: as shown in figure 3, the expression of Eya2mRNA has bright after A2780/Taxol cell transfects S1, S2, S3 respectively
Aobvious decline, wherein for S1 interference effect compared with negative control group, Eya2mRNA has lowered 77.76%, with S2 (42.31%) and S3
(51.84%) it compares, there were significant differences (P < 0.05).The result shows that S1 has best interference effect to Eya2.
Four, Western Blotting detects Eya2 protein expression
Detecting step is the same, after ECL development, with Image Quant LAS4000mini (GE Healthcare) to image
Scan process.
As a result: as shown in figure 4, compared with negative control, after S1 transfection, Eya2 protein expression in A2780/Taxol cell
It is remarkably decreased (P ﹤ 0.05), and there were significant differences (P ﹤ 0.05) compared with S2 and S3.The result shows that in taxol resistance strain
In A2780/Taxol, S1 has best interference effect to the protein expression of Eya2.Therefore pass through screening, after S1 is selected as
The siRNA of continuous research.
The building of 4. eukaryotic vector pLKO.1-Eya2-sh1 of embodiment and the interference effect of Eya2 gene expression is detected
One, experimental group:
Normal group of 1.A2780/Taxol (does not transfect any carrier), hereinafter referred to as AR；
2.A2780/Taxol negative control group (transfection pLKO.1puro empty carrier), hereinafter referred to as AR-N；
3.A2780/Taxol experimental group 1 (transfection pLKO.1-Eya2-sh1), hereinafter referred to as AR-sh1；
Two, Eya2-S1 segment is synthesized
Two restriction enzyme sites of Age I and EcoR I are selected, according to the sequence of S1, its shRNA sequence is designed and is building up to true
In nuclear expression carrier pLKO.1puro.Sequence is as follows:
Positive-sense strand:
5’-CCGGACTAGTTCTACCATTTCCTTGTATTCAAGAGATACAAGGAAATGGTAGAACTAGTTTTTTT
GGTACC-3'(SEQ ID NO.7)；
Antisense strand:
5’-AATTGGTACCAAAAAAACTAGTTCTACCATTTCCTTGTATCTCTTGAATACAAGGAAATGGTAGA
ACTAGT-3'(SEQ ID NO.8)；
Three, the building of eukaryotic vector pLKO.1-Eya2-sh1
PLKO.1-Eya2-sh1 recombinant expression carrier (Figures 5 and 6) are constructed with carrier for expression of eukaryon pLKO.1puro, specifically
Method is referring to U.S.'s Cold Spring Harbor Publications " Molecular Cloning:A Laboratory guide ".
By Eya2-S1 positive-sense strand and the annealed program of antisense strand (95 DEG C of denaturation 2min；Slow cooling is annealed to 25 DEG C), 4
DEG C save.Age I and EcoR I complete degestion carrier pLKO.1puro, 37 DEG C overnight；Digestion products DNA gel reclaim reagent
Box recycles DNA.Annealed product is attached with carrier digestion recycling segment to react, reaction system (10ul): T4 ligase 1ul,
T4 ligase buffer solution 1ul, annealed product and carrier digestion recycling segment mixture (molar ratio 3:1)；Deionized water mend to
10ul, 16 DEG C of connections are overnight；5ul connection product is taken to be placed in 100ul JM109 competent bacteria, ice bath 30min, 42 DEG C of heat are stopped
Gram 90s, ice bath 5min add LB culture medium 1000ul, and 37 DEG C of shaking table cultures 30min, 5000rpm are centrifuged 5min, abandon supernatant, will be thin
Bacterium is spread evenly across on LB plate (ampicillin containing 50ug/ml), 37 DEG C of inversion overnight incubations；Several independent clones are selected to connect
For kind in the LB culture medium containing corresponding resistant, bacterium is expanded in 37 DEG C of concussions overnight；Bacterium is collected, is extracted with plasmid DNA purification kit
Plasmid DNA is obtained, Kpn I digestion identification obtains pLKO.1-Eya2-sh1 recombinant plasmid.
Four, interference effect is observed after pLKO.1-Eya2-sh1 recombinant plasmid transfected cell
PLKO.1-Eya2-sh1 is transfected into the A2780/Taxol cell of logarithmic growth phase.Transfect reference
Lipofectamine3000 operational manual, every hole dilute 5ul with 125 μ l serum-free OPTI-MEM culture mediums
Lipofectamine3000 reagent simultaneously mixes well；5ug recombinant plasmid is added in 125 μ l serum-free OPTI-MEM culture mediums
DNA is added P3000 reagent 10ul, mixes well, preparation and reorganization plasmid premixed liquid；In diluted Lipofectamine
Recombinant plasmid premixed liquid (1:1) is added in 3000 reagents, is incubated at room temperature 5mim；Finally by recombinant plasmid-liposome complex
250ul is added in cell, and 37 DEG C, 5% CO2In continue to cultivate.Eya2 protein expression is detected after 72h.
As shown in fig. 7, after transfection pLKO.1-Eya2-sh1 recombinant plasmid, compared with negative control (transfection empty plasmid),
Eya2 protein expression is remarkably decreased (P ﹤ 0.05) in A2780/Taxol cell, the results showed that, transfection pLKO.1-Eya2-sh1 weight
Group plasmid can effectively interfere the protein expression of Eya2.
Embodiment 5. transfect pLKO.1-Eya2-sh1 specific inhibition Eya2 expression after to tumor cell proliferation, apoptosis, move
The influence for moving and invading
One, experimental group:
Normal group of 1.A2780/Taxol (does not transfect any carrier), hereinafter referred to as AR；
2.A2780/Taxol negative control group (transfection pLKO.1puro empty carrier), hereinafter referred to as AR-N；
3.A2780/Taxol experimental group (transfection pLKO.1-Eya2-sh1), hereinafter referred to as AR-sh1.
Two, grouping transfection
Transfection procedure is the same, continues to cultivate cell after transfection, for detecting proliferation, apoptosis, migration and the invasion of cell.
Three, cell proliferation test
Cell continues to cultivate 72h after transfecting pLKO.1-Eya2-sh1 in 96 orifice plates, and 10ulBrdU marking fluid is added in every hole
To the final concentration of 10uM of BrdU, 37 DEG C of incubation 2h；BrdU marking fluid is absorbed, 200ul FixDenat, 20 DEG C of incubations are added in every hole
30min；FixDenat is absorbed, 100ul anti-BrdU-POD, 20 DEG C of incubation 90min is added in every hole；Every hole 200ul
Washing Solution is washed 3 times；The hole 100ul/ substrate solution, 20 DEG C of incubation 20min, Detection wavelength 370nm (references are added
Wavelength 492nm) absorbance (A) is surveyed, the ability A of cell ProliferationExperimental group/AControl groupIt indicates.
As a result as shown in Figure 8 and Figure 9, after A2780/Taxol cell transfecting pLKO.1-Eya2-sh1, under phase contrast microscope
Experimental group cell quantity significantly reduces, rounded, and the rarer feeler stretching, extension of cell, cell fragment increases；Bromine mark method test cell
Proliferation results are shown: compared with negative control, experimental group ability of cell proliferation, which has dropped 54.82%, significant difference (P <
0.05).After the expression for illustrating specific inhibition Eya2, tumor cell proliferation can be inhibited.
Four, Caspase3 Activity determination Apoptosis
Cell is collected after transfection 72h, it is 1 × 10 that lysate, which adjusts cell density,8/ ml cracks 15min, 15000g on ice
× 20min collects supernatant.Prepare positive and yin simultaneously according to CaspACE Assay System (colorimetric) specification
Property control sample, measures and to adjust each group protein concentration identical.Caspace Assay is added in every hole in 96 orifice plates
Buffer32ul, DMSO2ul, 100nM DTT 10ul, it is 98ul that deionized water, which adjusts volume, and the bottom 2ul DEVD-pNA is added
Object, 37 DEG C of incubations 4h, Detection wavelength 405nM survey absorbance, calculate every group of sample Caspase3 activity with Δ A method.
The results are shown in Figure 10, and after A2780/Taxol cell transfecting pLKO.1-Eya2-sh1, Caspase3 activity increases
2.15 times, compared with negative control, there is significant difference (P < 0.05), after the expression for illustrating specific inhibition Eya2, can promote
Into apoptosis of tumor cells.
Five, cell scratch test detects cell migration ability
Horizontal line is uniformly drawn with ruler behind in six orifice plates, the standardized road about 0.5cm crosses via hole, every hole at least 6 cross
Line.After cell transfecting pLKO.1-Eya2-sh1, continue culture when cell fusion is at single layer state for 24 hours, is used in selection area
The pipette tips of 200ul vertical scratch in six orifice plates, PBS wash the cell under 3 removals are drawn, serum free medium are added and continues to train
It supports.0h, for 24 hours, 48h time point take pictures, and randomly select 6 horizontal lines, calculate iuntercellular apart from mean value.
As a result as shown in figure 11, pLKO.1-Eya2-sh1 transfects cell for 24 hours and after 48h, A2780/Taxol iuntercellular away from
From noticeably greater than negative control group, healing ability is remarkably decreased after cell scratch, illustrates the expression of specific inhibition Eya2, can be pressed down
The migration of tumour cell processed.
Six, Transwell testing inspection cell migration ability
It after cell transfecting 48h, with collected by trypsinisation, is resuspended with serum free medium, adjustment cell density is 5 × 105/
Ml, upper chamber add 2ml cell suspension, and lower room adds 10%FBS complete medium 2ml, continue culture for 24 hours, take out cell, and PBS washes 3
It is secondary, the cell of upper chamber upper surface is carefully removed with cotton swab, inversion is dried, and the fixed 25min of 95% ethyl alcohol, haematoxylin dyeing is shown
Micro- microscopic observation is counted, is taken pictures.Each cell counts 10 visuals field, is averaged statistics and analyzes changing for cell migration ability
Become.
Cell migration assay result as illustrated in fig. 12, transfect pLKO.1-Eya2-sh1 after, A2780/Taxol experimental group with
The cell quantity that negative control group penetrates cell is 103 ± 15 and 284 ± 29 respectively, and the two has statistical difference (P < 0.05)；
Should the result shows that, after the expression of specific inhibition Eya2, the migration of tumour cell can be inhibited.
Seven, Transwell testing inspection cell invasion ability
The matrigel that -20 DEG C are saved first liquefies in 4 DEG C of rewarmings, takes matrigel and OPTI-MEM to mix on ice with 1:6 dilute
It releases, is coated with the upper chamber face of cell bottom film, 37 DEG C of solidification 30min absorb the liquid of small indoor precipitation.Matrigel coating after remaining
Step is same as above, and each cell counts 10 visuals field, is averaged statistics and is analyzed the change of cell invasion ability.
Cell invasion experimental result is as shown in Figure 12 B, and A2780/Taxol experimental group penetrates the thin of cell with negative control group
Born of the same parents' quantity is 82 ± 15 and 179 ± 24 respectively, and the two has statistical difference (P < 0.05)；Should the result shows that, specific inhibition
After the expression of Eya2, tumor cell invasion can be inhibited.
To the reverse effect of ovarian cancer drug-resistant after embodiment 6.pLKO.1-Eya2-sh1 specific inhibition Eya2 expression
One, experimental group:
Normal group of 1.A2780 (does not transfect any carrier), hereinafter referred to as A；
Normal group of 2.A2780/Taxol (does not transfect any carrier), hereinafter referred to as AR；
3.A2780/Taxol negative control group (transfection pLKO.1puro empty carrier), hereinafter referred to as AR-N；
4.A2780/Taxol experimental group (transfection pLKO.1-Eya2-sh1), hereinafter referred to as AR-sh1.
Two, grouping transfection
Transfection procedure is the same, continues to cultivate cell for 24 hours after transfection.
Three, detection of the cell to paclitaxel-sensitive after transfection pLKO.1-Eya2-sh1
Each group logarithmic growth phase cell, cell is resuspended after pancreatin digestion, cell count and the density for adjusting cell suspension
It is 1 × 105/ ml is inoculated into 96 orifice plates and continues culture for 24 hours.Taxol is added in each group in next day, and concentration gradient is set respectively
200ug/ml, 100ug/ml, 50ug/ml, 25ug/ml, 12.5ug/ml, 6.25ug/ml, 3.125ug/ml, 0ug/ml, effect
After for 24 hours, absorbance (A) is surveyed in wavelength 370nm (reference wavelength 492nm) with bromine mark method, calculates suppression of the taxol to every group of cell
Rate processed, inhibiting rate=AExperimental group/ANegative control group.Each concentration sets 3 multiple holes, is averaged.
Drug concentration when inhibiting rate is 50% is half-inhibitory concentration (IC50)；
The IC of persister A2780/Taxol50With the IC of its parental cell strain A278050Ratio be drug resistance multiple
(Resistant Folder,RF)；
The IC of persister A2780/Taxol50The IC after pLKO.1-Eya2-sh1 (reversal agent) is transfected with it50Ratio be
Drug resistance inversion index (Reversal Index, RI).
As a result as shown in table 2, table 3, Figure 13, IC of the A2780/Taxol to taxol50(40.33 ± 4.57ug/ml) is significant
Higher than parent A2780 to the IC of taxol50(1.24 ± 0.46ug/ml), drug resistance multiple are up to 32.52, prompt A2780/Taxol
Parental cell A2780, height drug resistance are substantially less than to the sensibility of taxol.And when A2780/Taxol transfects pLKO.1-
After Eya2-sh1, the sensibility of taxol is significantly improved (5.79 ± 1.23ug/ml), transfects pLKO.1-Eya2-sh1 pairs
Clearly, reverse index is 6.67 to the reversing effect of A2780/Taxol taxol resistance.
Drug susceptibility of the table 2.A2780 and A2780/Taxol to taxol
Table 3. transfects reverse of the A2780/Taxol to taxol drug sensibility after pLKO.1-Eya2-sh1
SEQUENCE LISTING
<110>Zhejiang University
<120>siRNA and its recombinant vector of specificity inhibition Eya2 gene expression and application
<130>
<160> 8
<170> PatentIn version 3.3
<210> 1
<211> 21
<212> RNA
<213>artificial sequence
<400> 1
uaguucuacc auuuccuugu a 21
<210> 2
<211> 21
<212> RNA
<213>artificial sequence
<400> 2
caaggaaaug guagaacuag u 21
<210> 3
<211> 21
<212> RNA
<213>artificial sequence
<400> 3
aguuuaucca gacaaucgcu g 21
<210> 4
<211> 21
<212> RNA
<213>artificial sequence
<400> 4
gcgauugucu ggauaaacug a 21
<210> 5
<211> 21
<212> RNA
<213>artificial sequence
<400> 5
uuuguucugu gagucuuaca g 21
<210> 6
<211> 21
<212> RNA
<213>artificial sequence
<400> 6
guaagacuca cagaacaaaa g 21
<210> 7
<211> 71
<212> DNA
<213>artificial sequence
<400> 7
ccggactagt tctaccattt ccttgtattc aagagataca aggaaatggt agaactagtt 60
tttttggtac c 71
<210> 8
<211> 71
<212> DNA
<213>artificial sequence
<400> 8
aattggtacc aaaaaaacta gttctaccat ttccttgtat ctcttgaata caaggaaatg 60
gtagaactag t 71
Claims (4)
1. specificity inhibits application of the siRNA of Eya2 gene expression in the drug that preparation reverses oophoroma taxol resistance,
It is characterized in that, the siRNA includes positive-sense strand and antisense strand, the nucleotide sequence of the positive-sense strand such as SEQ ID NO.1 institute
Show, the nucleotide sequence of antisense strand is as shown in SEQ ID NO.2.
2. application as described in claim 1, which is characterized in that 3 bases at 5 ' and 3 ' ends of the positive-sense strand and antisense strand
Carry out the modification of 2 '-methoxyl groups.
3. a kind of recombinant vector of the DNA sequence dna for the siRNA for inhibiting Eya2 gene expression containing coding specificity is reversed in preparation
Application in the drug of oophoroma taxol resistance, which is characterized in that the siRNA includes positive-sense strand and antisense strand, it is described just
The nucleotide sequence of adopted chain is as shown in SEQ ID NO.1, and the nucleotide sequence of antisense strand is as shown in SEQ ID NO.2.
4. application as claimed in claim 3, which is characterized in that 3 bases at 5 ' and 3 ' ends of the positive-sense strand and antisense strand
Carry out the modification of 2 '-methoxyl groups.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201710547935.5A CN107287200B (en) | 2017-07-06 | 2017-07-06 | The siRNA and its recombinant vector of specificity inhibition Eya2 gene expression and application |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201710547935.5A CN107287200B (en) | 2017-07-06 | 2017-07-06 | The siRNA and its recombinant vector of specificity inhibition Eya2 gene expression and application |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN107287200A CN107287200A (en) | 2017-10-24 |
| CN107287200B true CN107287200B (en) | 2019-11-22 |
Family
ID=60099969
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201710547935.5A Expired - Fee Related CN107287200B (en) | 2017-07-06 | 2017-07-06 | The siRNA and its recombinant vector of specificity inhibition Eya2 gene expression and application |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN107287200B (en) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN110522759B (en) * | 2019-08-15 | 2022-08-26 | 广州医科大学 | Application of miR-517b-3p inhibitor in treatment of paclitaxel drug-resistant breast cancer |
| CN114480657A (en) * | 2022-03-10 | 2022-05-13 | 中国医科大学附属盛京医院 | Marker of ovarian cancer and application thereof |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2009108706A3 (en) * | 2008-02-25 | 2009-12-10 | The Regents Of The University Of Colorado, A Body Corporate | Methods for inhibiting six 1 and eya proteins |
-
2017
- 2017-07-06 CN CN201710547935.5A patent/CN107287200B/en not_active Expired - Fee Related
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2009108706A3 (en) * | 2008-02-25 | 2009-12-10 | The Regents Of The University Of Colorado, A Body Corporate | Methods for inhibiting six 1 and eya proteins |
Non-Patent Citations (2)
| Title |
|---|
| Eya2,a Target Activated by Plzf,Is Critical for PLZF-RARA-Induced Leukemogenesis;Ryoichi Ono et al;《Molecular and Cellular Biology》;20170417;第37卷(第13期);e00585-16 * |
| 人eya2基因小干扰RNA表达载体的构建及表达;袁斌等;《生物技术通讯》;20080331;第19卷(第2期);第81-84 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN107287200A (en) | 2017-10-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Liu et al. | FTO promotes cell proliferation and migration in esophageal squamous cell carcinoma through up-regulation of MMP13 | |
| He et al. | Expression of galectin‐1 in carcinoma‐associated fibroblasts promotes gastric cancer cell invasion through upregulation of integrin β1 | |
| Gong et al. | LncRNA HAND2‐AS1 represses cervical cancer progression by interaction with transcription factor E2F4 at the promoter of C16orf74 | |
| Ge et al. | AntagomiR-27a targets FOXO3a in glioblastoma and suppresses U87 cell growth in vitro and in vivo | |
| Zeng et al. | Up-regulation of kin17 is essential for proliferation of breast cancer | |
| Fei et al. | FoxM1 is associated with metastasis in colorectal cancer through induction of the epithelial‑mesenchymal transition | |
| Li et al. | Long noncoding RNA AC114812. 8 promotes the progression of bladder cancer through miR-371b-5p/FUT4 axis | |
| Wu et al. | LncRNA SLCO4A1-AS1 modulates colon cancer stem cell properties by binding to miR-150-3p and positively regulating SLCO4A1 | |
| Liu et al. | MicroRNA-27b inhibits Spry2 expression and promotes cell invasion in glioma U251 cells | |
| CN107287200B (en) | The siRNA and its recombinant vector of specificity inhibition Eya2 gene expression and application | |
| Zhu et al. | Circular RNA circ_0010235 sponges miR-338-3p to play oncogenic role in proliferation, migration and invasion of non-small-cell lung cancer cells through modulating KIF2A | |
| Wang et al. | Circ-PRKDC facilitates the progression of colorectal cancer through miR-198/DDR1 regulatory axis | |
| Park et al. | Follicular stimulating hormone enhances Notch 1 expression in SK-OV-3 ovarian cancer cells | |
| Sheng et al. | Long-chain non-coding SOX21-AS1 promotes proliferation and migration of breast cancer cells through the PI3K/AKT signaling pathway | |
| Dong et al. | LINC00052 promotes breast cancer cell progression and metastasis by sponging miR‑145‑5p to modulate TGFBR2 expression | |
| CN107236736B (en) | The siRNA and its recombinant vector of specificity inhibition MSI-1 gene expression and application | |
| Liu et al. | MiRNA-375 inhibits retinoblastoma progression through targeting ERBB2 and inhibiting MAPK1/MAPK3 signalling pathway | |
| CN107254470B (en) | The siRNA and its recombinant vector of specificity inhibition PADI2 gene expression and application | |
| CN107354157B (en) | siRNA for specifically inhibiting LAMB1 gene expression, recombinant vector and application thereof | |
| CN107541514A (en) | Specificity suppresses siRNA and its recombinant vector and the application of COL12A1 gene expressions | |
| CN107267518B (en) | The siRNA and its recombinant vector of specificity inhibition CLDN8 gene expression and application | |
| Lu et al. | Suppression of HER-2 via siRNA interference promotes apoptosis and decreases metastatic potential of SKOV‑3 human ovarian carcinoma cells | |
| CN107541515A (en) | Specificity suppresses siRNA and its recombinant vector and the application of PRV1 gene expressions | |
| CN107164378A (en) | Specificity suppresses siRNA and its recombinant vector and the application of SPIB gene expressions | |
| CN104531760A (en) | Interference plasmid of short hairpin RNA of Dp71 protein and application of interference plasmid |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant | ||
| CF01 | Termination of patent right due to non-payment of annual fee | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20191122 |